The current classification depends on clinicopathological factors such as age, tumor size, presence of comedo necrosis, nuclear grade, and hormone receptor and human epidermal growth factor receptor 2 (HER2) status15–19, and in the absence of a global standard20, the evaluations vary among pathologists or institutions. The gene discussed is ERBB2; the disease is neoplasm.